Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yi-Chiu Kuo"'
Autor:
Christine Brown, Wen-Chung Chang, Renate Starr, Brenda Aguilar, Kurt Jenkins, Miso Park, Cheng-Fu Kuo, Yi-Chiu Kuo, Alfur Fu-Hsin Hung, Jonathan Hibbard, John C Williams
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/00815edf8a0d46179f8ab9de3455b390
Autor:
John Williams, Christine Brown, Brenda Aguilar, Stephen Forman, Miso Park, Cheng-Fu Kuo, Yi-Chiu Kuo, Zhen Tong, Agata Xella, Vanessa Salvary
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6e71636acca7478398f6ce3e0e39ecd5
Autor:
Sophia G Liva, Yu‐Chou Tseng, Anees M Dauki, Michael G Sovic, Trang Vu, Sally E Henderson, Yi‐Chiu Kuo, Jason A Benedict, Xiaoli Zhang, Bryan C Remaily, Samuel K Kulp, Moray Campbell, Tanios Bekaii‐Saab, Mitchell A Phelps, Ching‐Shih Chen, Christopher C Coss
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 2, Pp n/a-n/a (2020)
Abstract No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse and
Externí odkaz:
https://doaj.org/article/e590447d2f534e9b86dfa986d39f3eb8
Autor:
Yi-Chiu Kuo, 郭憶萩
98
Ovarian cancer patients are always diagnosed at an advanced stage resulting in poor survival rates. So far ovarian cancer is the eighth cause of cancer deaths among women. To study the effects of MT-6, a derivative of moscatilin, on human ova
Ovarian cancer patients are always diagnosed at an advanced stage resulting in poor survival rates. So far ovarian cancer is the eighth cause of cancer deaths among women. To study the effects of MT-6, a derivative of moscatilin, on human ova
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/92461219141899188220
Autor:
Hao-Kang Li, Tai-Sheng Wu, Yi-Chiu Kuo, Ching-Wen Hsiao, Hsiu-Ping Yang, Chia-Yun Lee, Pei-Ju Leng, Zih-Fei Cheng, Sen-Han Yang, Yang-Liang Lin, Shih-Chia Hsiao, Sai-Wen Tang
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Hao-Kang Li, Tai-Sheng Wu, Pei-Ru Leng, Yi-Chiu Kuo, Zih-Fei Cheng, Chia-Yun Lee, Yan-Liang Lin, Sai-Wen Tang, Shih-Chia Hsiao
Publikováno v:
Cancer Research. 83:LB089-LB089
Introduction: CAR-αβT therapies have been shown to improve clinical outcomes in hematological malignancies; however, solid tumors still remain as challenges to CAR-αβT therapies due to tumor microenvironment, limited tumor infiltration or antigen
Autor:
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C Williams
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e003752
BackgroundChimeric antigen receptor (CAR) T cells engineered to recognize and target tumor associated antigens have made a profound impact on the quality of life for many patients with cancer. However, tumor heterogeneity and intratumoral immune supp
Autor:
Samuel K. Kulp, Michael G. Sovic, Xiaoli Zhang, Tanios Bekaii-Saab, Yi Chiu Kuo, Bryan Remaily, Moray J. Campbell, Trang Vu, Anees M. Dauki, Mitchell Phelps, Jason A. Benedict, Sophia G. Liva, Christopher C. Coss, Yu Chou Tseng, Sally E. Henderson, Ching-Shih Chen
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 2, Pp n/a-n/a (2020)
EMBO Molecular Medicine
EMBO Molecular Medicine
No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, i
Autor:
Agata Xella, Christine E. Brown, Miso Park, Cheng-Fu Kuo, Zhen Tong, Vanessa Salvary, Yi-Chiu Kuo, John C. Williams, Brenda Aguilar, Stephen J. Forman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMeditope is a small cyclic peptide that was identified to bind to cetuximab within the Fab region. The meditope binding site can be grafted onto any Fab framework, creating a platform to uniquely and specifically target monoclonal antibodie
Autor:
Jeremy D. King, Christine E. Brown, Victor Kenyon, Yi-Chiu Kuo, Wen-Chung Chang, Lawrence A. Stern, Cheng-Fu Kuo, John C. Williams, Miso Park
Publikováno v:
Cancer Research. 80:6591-6591
Adoptive T cell transfer of engineered T cells with a chimeric antigen receptor (CAR) can harness the patients' immune system to recognize a specific antigen and redirect T cells to target disease. Conventional CAR T cells, however, are specific to a